Sutro Biopharma, Inc. is a clinical-stage biotechnology company focused on the discovery, development, and manufacturing of innovative therapeutic products. Its primary objective is to create protein-based treatments for challenging conditions like cancer and autoimmune disorders. The company achieves this through its proprietary XpressCF+ platform, a unique technology that integrates cell-free protein synthesis with precise, site-specific drug conjugation. Currently, Sutro's pipeline features two lead antibody-drug conjugate (ADC) candidates, both undergoing Phase 1 clinical evaluation. STRO-001 targets the CD74 protein, designed for individuals with multiple myeloma and non-Hodgkin lymphoma. The second candidate, STRO-002, is engineered to bind to folate receptor-alpha, intended for the treatment of ovarian and endometrial cancers. Strategic alliances are also a key part of its strategy, including collaborations and licensing agreements. A partnership with Merck aims to advance research programs involving cytokine derivatives for both oncological and autoimmune applications. Additionally, an agreement with Celgene Corporation focuses on identifying and developing bispecific antibodies and/or ADCs specifically within the immuno-oncology domain. Founded in 2003, the company initially operated under the name Fundamental Applied Biology, Inc. Its corporate headquarters are located in South San Francisco, California.
| Metric | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $62.04M | $153.73M | $67.77M | $61.88M | $42.72M | $42.74M | $38.42M | $51.74M |
| Cost of Revenue | $7.22M | $6.82M | $8.29M | $9.77M | $76.96M | N/A | $54.26M | $51.90M |
| Gross Profit | $54.83M | $146.91M | $59.48M | $52.11M | $-34.24M | $42.74M | $-15.84M | $-156.00K |
| Gross Margin | 88.37% | 95.57% | 87.77% | 84.21% | -80.14% | 100.00% | -41.24% | -0.30% |
| Operating Expenses | $293.28M | $236.19M | $188.43M | $150.63M | $36.82M | $98.20M | $21.38M | $19.12M |
| Operating Income | $-238.45M | $-89.28M | $-128.94M | $-98.52M | $-71.06M | $-55.47M | $-37.22M | $-19.27M |
| Operating Margin | -384.34% | -58.07% | -190.26% | -159.22% | -166.32% | -129.79% | -96.89% | -37.25% |
| Net Income | $-227.46M | $-106.79M | $-119.20M | $-105.54M | $-32.13M | $-55.74M | $-35.32M | $-19.69M |
| Net Margin | -366.62% | -69.47% | -175.89% | -170.55% | -75.20% | -130.44% | -91.93% | -38.05% |
| EPS (Basic) | $-29.60 | $-17.80 | $-23.50 | $-22.90 | $-9.90 | $-24.30 | $-15.50 | $-28.10 |
| EBITDA | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Stock Option Compensation Expense | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Price To Earnings Ratio | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Price To Sales Ratio | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Shares Outstanding | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Market Capitalization | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |